Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
151 hedge funds and large institutions have $1.25B invested in Aimmune Therapeutics in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 69 increasing their positions, 34 reducing their positions, and 26 closing their positions.
103% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 34
72% more call options, than puts
Call options by funds: $7.2M | Put options by funds: $4.19M
3% less funds holding
Funds holding: 155 → 151 (-4)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
15% less capital invested
Capital invested by funds: $1.48B → $1.25B (-$227M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.6M |
| 2 |
BlackRock
New York
|
+$17.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$16M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$10.9M |
| 5 |
Morgan Stanley
New York
|
+$7.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$28.7M |
| 2 |
TG
TLP Group
Evanston,
Illinois
|
-$18.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$17.5M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$10.8M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$9.77M |
AIMT Hedge Fund Activity: Q2 2018 in Review
151 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q2 2018, worth a combined $1.25B — down 15% from $1.48B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of AIMT and 22 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 69 added.
The largest buyer was Point72 Asset Management, adding an estimated $18.6M. The largest seller was Great Point Partners, exiting entirely with an estimated $28.7M sold.
- 151 institutional investors held Aimmune Therapeutics (AIMT) as of Q2 2018, down from 155 in Q1 2018.
- Funds reported $1.25B of Aimmune Therapeutics stock for Q2 2018, down 15% quarter-over-quarter.
- 22 funds opened new Aimmune Therapeutics positions in Q2 2018 and 26 closed out, a net change of -4 holders.
- The largest Aimmune Therapeutics buyer in Q2 2018 was Point72 Asset Management, an estimated $18.6M added.
- The largest Aimmune Therapeutics seller in Q2 2018 was Great Point Partners, an estimated $28.7M sold.
Based on aggregated 13F filings for Q2 2018.